Asia FX weakens slightly, rupee recovers from record low as RBI holds rates
Investing.com -- DocMorris recently announced its preliminary first quarter results for 2025, which matched market expectations. The company reported a 13.4% increase in group-level revenues, reaching CHF 296.5m, slightly above the consensus of CHF 296m.
Additionally, prescription revenues saw a significant rise of 52%, totaling CHF 53.9m, slightly surpassing the consensus forecast of CHF 53.7m.
For the full fiscal year 2025, DocMorris anticipates sales growth of more than 10% and an adjusted EBITDA ranging between a loss of CHF 35m and CHF 55m. This forecast is somewhat more conservative than the market consensus, which predicted a sales growth of 17% and a smaller EBITDA loss of CHF 17m.
In addition to its annual forecast, DocMorris also issued a new mid-term outlook. The company expects to see revenues grow at a rate of 20% per annum and aims to reach breakeven EBITDA in the course of 2026. These projections align broadly with current market expectations.
DocMorris also confirmed plans for a capital raise of CHF 200m, which has been fully underwritten by a banking syndicate. The company will reveal the specifics of this capital raise at its Annual General Meeting (AGM) on 8 May 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.